Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NeoTX Therapeutics Ltd.
Incyte Corporation
Numab Therapeutics AG
Checkpoint Therapeutics, Inc.
Prelude Therapeutics
Multitude Therapeutics Inc.
Xencor, Inc.
Abramson Cancer Center at Penn Medicine
Chinese PLA General Hospital
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)